|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Narvekar appointed as new Maharashtra FDA Commissioner
|
|
Saturday, 30 November, 2024, 08 : 00 AM [IST]
|
|
Shardul Nautiyal, Mumbai
|
 The Maharashtra Government has appointed Rajesh Janardhan Narvekar, as the new Commissioner of Food and Drug Administration (FDA), Maharashtra, following the retirement of former FDA Commissioner Abhimanyu Kale.
Narvekar’s appointment marks a significant step in strengthening Maharashtra's regulatory and public health infrastructure.
Narvekar, a 2009 batch IAS officer, holds a Master’s degree in History and brings decades of administrative experience to the role. He began his career in 1994 as a Deputy Collector in the Maharashtra Administrative Services and has since worked across various key departments and roles as Deputy Collector in MHADA and the Stamp Duty & Registration Department, Additional Collector, held positions such as Deputy Chief Executive at Maharashtra Industrial Development Corporation (MIDC) and Deputy Secretary in the Revenue Department.
He also served in senior IAS roles like the Chief Executive Officer (CEO), Zilla Parishad, Raigad District (2016–2017), District Collector, Thane (2018–2022) and Municipal Commissioner, Navi Mumbai Municipal Corporation (Oct 2022–Mar 2023).
Narvekar’s tenure is marked by significant achievements, including his contributions to international collaborations such as the Delhi-Mumbai Industrial Corridor project, where he underwent specialised training in Osaka, Japan.
Over his career, Narvekar has received several prestigious awards, including recognition for excellence in the Swachh Bharat Mission, Best District Election Officer award from the Election Commission of India for smooth conduct of the 2019 Lok Sabha and Vidhan Sabha elections, the Hon. Governor of Maharashtra Award for his dedicated service during the Covid-19 pandemic.
As the Commissioner of FDA, Narvekar is expected to steer the department with a focus on public health and safety, ensuring stringent regulatory oversight of food and pharmaceutical standards.
His extensive experience in governance, coupled with his exposure to international best practices through study programmes in countries like USA, South Korea, and Italy positions him as a leader capable of addressing the growing challenges in the FDA’s mandate.
|
|
|
|
|
|
|
|
|
|